Alar Pharmaceuticals Inc. (TPEX:6785)
Taiwan
· Delayed Price · Currency is TWD 133.00
+2.00 (1.53%)
Apr 2, 2025, 1:30 PM CST
Alar Pharmaceuticals Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 1,406 | 739.46 | 455.35 | 519.07 | 560.96 | Upgrade
|
| Short-Term Investments | 1,025 | 156.53 | 30.87 | - | - | Upgrade
|
| Cash & Short-Term Investments | 2,431 | 895.99 | 486.22 | 519.07 | 560.96 | Upgrade
|
| Cash Growth | 171.32% | 84.28% | -6.33% | -7.47% | 227.56% | Upgrade
|
| Receivables | - | - | 0.84 | - | - | Upgrade
|
| Prepaid Expenses | 2 | 3.56 | 9.96 | 9.62 | 7.7 | Upgrade
|
| Other Current Assets | 8.58 | 3.47 | 0.55 | 0.01 | 22.76 | Upgrade
|
| Total Current Assets | 2,442 | 903.02 | 497.57 | 528.69 | 591.42 | Upgrade
|
| Property, Plant & Equipment | 13.58 | 12.77 | 9.78 | 9.1 | 7.75 | Upgrade
|
| Long-Term Investments | 21.46 | - | - | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | 48.27 | 54.97 | 13 | - | - | Upgrade
|
| Other Long-Term Assets | 31.2 | 2.45 | 2.25 | 2.11 | 4.8 | Upgrade
|
| Total Assets | 2,556 | 973.21 | 522.6 | 539.91 | 603.98 | Upgrade
|
| Accrued Expenses | 6.69 | 20.48 | 2.02 | 2.17 | 2 | Upgrade
|
| Current Portion of Leases | 0.3 | 1.27 | 1.29 | 0.68 | 0.91 | Upgrade
|
| Current Income Taxes Payable | 45.67 | 49.45 | - | - | - | Upgrade
|
| Current Unearned Revenue | 1.25 | 1.25 | - | - | - | Upgrade
|
| Other Current Liabilities | 1.16 | 2.32 | 2.06 | 1.61 | 1.22 | Upgrade
|
| Total Current Liabilities | 55.08 | 74.77 | 5.37 | 4.46 | 4.13 | Upgrade
|
| Long-Term Leases | 0.31 | 0.14 | 1.41 | 0.27 | 0.61 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 7.39 | - | 0.33 | - | - | Upgrade
|
| Other Long-Term Liabilities | 1.49 | 1.18 | 0.99 | 0.81 | 0.63 | Upgrade
|
| Total Liabilities | 64.26 | 76.09 | 8.1 | 5.54 | 5.37 | Upgrade
|
| Common Stock | 668 | 570 | 570 | 570 | 570 | Upgrade
|
| Additional Paid-In Capital | 1,579 | - | - | 424.04 | 424.04 | Upgrade
|
| Retained Earnings | 245.09 | 327.12 | -55.5 | -459.67 | -395.44 | Upgrade
|
| Shareholders' Equity | 2,492 | 897.12 | 514.5 | 534.37 | 598.6 | Upgrade
|
| Total Liabilities & Equity | 2,556 | 973.21 | 522.6 | 539.91 | 603.98 | Upgrade
|
| Total Debt | 0.6 | 1.41 | 2.69 | 0.95 | 1.52 | Upgrade
|
| Net Cash (Debt) | 2,430 | 894.58 | 483.53 | 518.12 | 559.44 | Upgrade
|
| Net Cash Growth | 171.69% | 85.01% | -6.68% | -7.39% | 231.33% | Upgrade
|
| Net Cash Per Share | 36.70 | 15.68 | 8.48 | 9.09 | 11.21 | Upgrade
|
| Filing Date Shares Outstanding | 66.8 | 57 | 57 | 57 | 57 | Upgrade
|
| Total Common Shares Outstanding | 66.8 | 57 | 57 | 57 | 57 | Upgrade
|
| Working Capital | 2,387 | 828.25 | 492.2 | 524.24 | 587.3 | Upgrade
|
| Book Value Per Share | 37.30 | 15.74 | 9.03 | 9.37 | 10.50 | Upgrade
|
| Tangible Book Value | 2,492 | 897.12 | 514.5 | 534.37 | 598.6 | Upgrade
|
| Tangible Book Value Per Share | 37.30 | 15.74 | 9.03 | 9.37 | 10.50 | Upgrade
|
| Machinery | 27.15 | 22.99 | 16.65 | 16.42 | 12.07 | Upgrade
|
| Leasehold Improvements | 0.98 | 0.98 | 0.98 | 1.05 | 1.05 | Upgrade
|
Updated Mar 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.